Teva’s CEO took a generous pay cut last year
Teva Pharmaceutical (TEVA) currently trades at $8.44 and has grown by 12% in the past 24 hours. Teva has undergone a massive transformation in the past two years after a $3 billion restructuring fundamentally reshaped the Israeli drugmaker’s operations. The man who led that charge, CEO Kåre Schultz, saw a big pay cut last year but will take solace with an extension that will keep him onboard until at least 2023.
Based on this information, investorsQ rates this stock a 5 out of 10. We give it this rating because Schultz secured $11.6 million in total pay in 2019, down more than $20 million from his $33 million windfalls the year before, according to a proxy filing. The high forecast for Teva Pharmaceutical is $16 and the low is $7. Notably, the company’s market cap is $9.25 billion with a 52 week high of $15.91 and a 52 week low of $6.07.